Source comparison
IGF-1 LR3 Dosage Hyperplasia 2026: Protocol Comparison
The table below compares three research-standard IGF-1 LR3 dosing protocols used in 2026 hyperplasia studies, showing dose structure, cycle design, and projected receptor preservation. Conservative Split-Dose 40mcg 20mcg AM / 20mcg PM 4 weeks on, 3 weeks off,
This comparison does not assign a generated winner or score.
- The table below compares three research-standard IGF-1 LR3 dosing protocols used in 2026 hyperplasia studies, showing dose structure, cycle design, and projected receptor preservation.
- Conservative Split-Dose
- 40mcg
- 20mcg AM / 20mcg PM
- 4 weeks on, 3 weeks off, repeat 2–3 cycles
- 75–80% of baseline
- Moderate, sustained across cycles
- Best for multi-cycle research with minimal receptor fatigue
- Moderate Single-Dose
- 60mcg
- 60mcg pre-bed
- 4 weeks on, 2 weeks off, repeat 2 cycles
- 65–70% of baseline
- High, but receptor decline limits repeat cycles
- Suitable for single-cycle studies; less effective in sequential protocols
- Aggressive Continuous
- 100mcg
- 100mcg AM
- 6 weeks continuous, no cycle
- 45–55% of baseline
- Highest initial response, but plateaus by week 3
- Not recommended; receptor desensitisation negates dose advantage